These cytokines and chemokines enhance the response of pMMR CRC and melanoma to anti-PD-1 therapy, providing a new approach for the combination of immune checkpoint inhibitors and methyltransferase inhibitors in the treatment of CRC and melanoma [73]. The gene discussed is PDCD1; the disease is melanoma.